Accelerating Biologics Development
simultaneously optimize affinity, developability, and safety with in vivo B cell display
Our Platform
How does it work?
  1. Primary B cells engineered to express biologic
  2. Engineered B cells engrafted into mice
  3. Mice immunized with drug target
  4. Engineered cells affinity mature in germinal centers
  5. Improved clones isolated and characterized
Why does it work?
  1. Innovative editing method promotes somatic hypermutation
  2. Genuine mammalian post-translational modifications
  3. Affinity maturation efficiently explores sequence space
  4. Selects against sequences with poor in vivo behavior
Edited B cells introduced into a mouse undergo affinity maturation to produce improved biologics
Read more:
Our Team
Mai Tran
Mai Tran, PhD
CEO
Tianling Ou
Tianling Ou, PhD
Senior Scientific Lead
Andi Pan
Andi Pan, PhD
Scientific Advisor
Charles Bailey
Charles Bailey, DVM
Senior Scientific Lead
Mike Farzan
Mike Farzan, PhD
Advisory Board Chair
Contact Us
inquiries@nuwagen.bio
Nuwagen Company Logo
Platform
Team
Contact